CN Patent

CN119656101A — 一种长效缓释溶致液晶凝胶制剂及制备方法

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2025-03-21 · 1y expired

What this patent protects

本发明公开了一种长效缓释溶致液晶凝胶制剂及其制备方法和应用，所述制剂包括基质材料、助溶剂和原料药物，其具有六角相的微观结构，表现出超过72h甚至高达170h的缓释效果，可延长药物半衰期近10倍，能够实现镇痛或镇痛与抗炎的双重疗效。

USPTO Abstract

本发明公开了一种长效缓释溶致液晶凝胶制剂及其制备方法和应用，所述制剂包括基质材料、助溶剂和原料药物，其具有六角相的微观结构，表现出超过72h甚至高达170h的缓释效果，可延长药物半衰期近10倍，能够实现镇痛或镇痛与抗炎的双重疗效。

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

Patent Metadata

Patent number: CN119656101A
Jurisdiction: CN
Classification: —
Expires: 2025-03-21
Drug substance claim: No
Drug product claim: No
Assignee: Qilu Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.